Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
After Plunging 19.8% in 4 Weeks, Here's Why the Trend Might Reverse for Ocular Therapeutix (OCUL)
11:30am, Tuesday, 27'th Jul 2021
The heavy selling pressure might have exhausted for Ocular Therapeutix (OCUL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera
3 Top Life Science Stocks to Buy on Sale Right Now
08:43am, Sunday, 11'th Jul 2021
Shares of these overlooked gems could make investors very rich once the rest of the market notices their value.
Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options
09:46am, Thursday, 20'th May 2021
Investors need to pay close attention to Ocular Therapeutix (OCUL) stock based on the movements in the options market lately.
Ocular Therapeutix: Catalysts Stacking
10:35am, Thursday, 06'th May 2021
Ocular Therapeutix is a multi-bagger stock with substantial upsides. Despite over two-fold gains, I believe it can appreciate higher due to pending catalysts. Dextenza is poised to gain the label expa
Ocular Therapeutix's (OCUL) CEO Antony Mattessich on Q1 2021 Results - Earnings Call Transcript
09:45pm, Wednesday, 05'th May 2021
Ocular Therapeutix's (OCUL) CEO Antony Mattessich on Q1 2021 Results - Earnings Call Transcript
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Please replace the release dated April 29, 2021, with the following corrected version due to multiple revisions. The updated release: OCULAR THERAPEUT
OCUL Stock: From $15.61 To Over $18 Explanation
01:46pm, Thursday, 29'th Apr 2021
The stock price of Ocular Therapeutix Inc (NASDAQ: OCUL) increased from $15.61 to over $18 during intraday trading. This is why it happened.
Ocular Therapeutix: Good Medicine, High Competition
11:04am, Thursday, 22'nd Apr 2021
Ocular Therapeutix: Good Medicine, High Competition
Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q4 2020 Results - Earnings Call Transcript
10:35pm, Thursday, 11'th Mar 2021
Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q4 2020 Results - Earnings Call Transcript
Ocular Therapeutix (OCUL) Reports Q4 Loss, Lags Revenue Estimates
06:10pm, Thursday, 11'th Mar 2021
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -27.78% and -4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
01:40pm, Thursday, 04'th Mar 2021
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix Shares Are Trading Higher As Company Starts Dosing In Mid-Stage Therapy Study For Dry Eye Disease
01:03pm, Monday, 01'st Mar 2021
Ocular Therapeutix Inc (NASDAQ: OCUL) has dosed the first patient in its Phase 2 trial evaluating OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of the sig
Ocular Therapeutix™ To Report Fourth Quarter and Year End 2020 Financial Results
08:00am, Thursday, 25'th Feb 2021
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative t
Ocular Therapeutix's Intravitreal Implant Shows Decrease In Retinal Fluid In Early-Stage Wet AMD Study
05:43am, Tuesday, 16'th Feb 2021
Ocular Therapeutix Inc (NASDAQ: OCUL) on Friday released limited data from its presentation on the ongoing Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration and other retin
